File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0753-3322(05)80053-8
- Scopus: eid_2-s2.0-33644531022
- PMID: 16507400
- WOS: WOS:000234423600013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma
Title | The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma |
---|---|
Authors | |
Keywords | Angiogenesis Cyclooxygenase-2 Hepatocellular carcinoma Vascular endothelial growth factor |
Issue Date | 2005 |
Publisher | Elsevier France, Editions Scientifiques et Medicales. The Journal's web site is located at http://www.elsevier.com/locate/biopha |
Citation | Biomedicine And Pharmacotherapy, 2005, v. 59 SUPPL. 2, p. S311-S316 How to Cite? |
Abstract | Hepatocellular carcinoma (HCC) is one of the five most common malignancies in the world and is the second leading cause of death in Hong Kong. Previous studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including HCC, suggesting that abnormal COX-2 expression plays an important role in carcinogenesis. In addition, some evidence suggests that selective COX-2 inhibitors suppress the formation of tumors in experimental models. However, there are no data in the literature on using COX-2 as an inhibitor target in HCC. The main objective of this article was to give a brief summary of the recent findings of the role of COX-2 in HCC. We briefly reviewed the significance of COX-2 in varies cancers, and then focused on the recent findings of the significance of COX-2 in HCC. Finally, we further evaluated the possibility of using COX-2 as a therapeutic target in HCC. © 2005 Elsevier SAS. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/172905 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 1.493 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tang, TCM | en_US |
dc.contributor.author | Poon, RTP | en_US |
dc.contributor.author | Fan, ST | en_US |
dc.date.accessioned | 2012-10-30T06:25:43Z | - |
dc.date.available | 2012-10-30T06:25:43Z | - |
dc.date.issued | 2005 | en_US |
dc.identifier.citation | Biomedicine And Pharmacotherapy, 2005, v. 59 SUPPL. 2, p. S311-S316 | en_US |
dc.identifier.issn | 0753-3322 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/172905 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is one of the five most common malignancies in the world and is the second leading cause of death in Hong Kong. Previous studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including HCC, suggesting that abnormal COX-2 expression plays an important role in carcinogenesis. In addition, some evidence suggests that selective COX-2 inhibitors suppress the formation of tumors in experimental models. However, there are no data in the literature on using COX-2 as an inhibitor target in HCC. The main objective of this article was to give a brief summary of the recent findings of the role of COX-2 in HCC. We briefly reviewed the significance of COX-2 in varies cancers, and then focused on the recent findings of the significance of COX-2 in HCC. Finally, we further evaluated the possibility of using COX-2 as a therapeutic target in HCC. © 2005 Elsevier SAS. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier France, Editions Scientifiques et Medicales. The Journal's web site is located at http://www.elsevier.com/locate/biopha | en_US |
dc.relation.ispartof | Biomedicine and Pharmacotherapy | en_US |
dc.rights | Biomedicine & Pharmacotherapy. Copyright © Elsevier France, Editions Scientifiques et Medicales. | - |
dc.subject | Angiogenesis | - |
dc.subject | Cyclooxygenase-2 | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Vascular endothelial growth factor | - |
dc.subject.mesh | Carcinoma, Hepatocellular - Enzymology - Pathology | en_US |
dc.subject.mesh | Cyclooxygenase 2 - Biosynthesis | en_US |
dc.subject.mesh | Cyclooxygenase 2 Inhibitors - Therapeutic Use | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver Neoplasms - Enzymology - Pathology | en_US |
dc.title | The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma | en_US |
dc.type | Article | en_US |
dc.identifier.email | TungPing Poon, R: poontp@hkucc.hku.hk | en_US |
dc.identifier.email | Fan, ST: stfan@hku.hk | en_US |
dc.identifier.authority | TungPing Poon, R=rp00446 | en_US |
dc.identifier.authority | Fan, ST=rp00355 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0753-3322(05)80053-8 | en_US |
dc.identifier.pmid | 16507400 | - |
dc.identifier.scopus | eid_2-s2.0-33644531022 | en_US |
dc.identifier.hkuros | 116882 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33644531022&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 59 | en_US |
dc.identifier.issue | SUPPL. 2 | en_US |
dc.identifier.spage | S311 | en_US |
dc.identifier.epage | S316 | en_US |
dc.identifier.isi | WOS:000234423600013 | - |
dc.publisher.place | France | en_US |
dc.identifier.scopusauthorid | ChiMan Tang, T=12751846600 | en_US |
dc.identifier.scopusauthorid | TungPing Poon, R=7103097223 | en_US |
dc.identifier.scopusauthorid | Fan, ST=7402678224 | en_US |
dc.customcontrol.immutable | jt 2014-05-05 | - |
dc.identifier.issnl | 0753-3322 | - |